당뇨병성 신경병증 시장 점유율, 규모, 동향 및 전망.

Diabetic neuropathy is a type of nerve damage that occurs due to high blood sugar levels in people with diabetes. It often affects the nerves in the legs and feet, causing symptoms such as pain, tingling, numbness, or weakness. The condition can also affect the digestive system, heart, and other parts of the body, depending on which nerves are affected. Effectively managing blood sugar levels and early intervention are important to slow the progression. Treatment focuses on relieving symptoms and preventing further complications.

 

The global diabetic neuropathy market was valued at USD 3,775.4 million in 2022 and is expected to witness a lucrative growth by reaching USD 6,298.1 million by 2031. The diabetic neuropathy market is expected to witness a CAGR of 6.7% during the forecast period (2024-2031).

 

Market Dynamics:

The growing prevalence of diabetes is accelerating the growth of the global diabetic neuropathy market. 

According to a 2021 report from the International Diabetes Federation, an estimated 537 million adults (aged 20–79) have diabetes, and this number is expected to increase to 643 million by 2030 and 783 million by 2045.

Surprisingly, about 75% of adults with diabetes live in low- and middle-income countries, and about half of all adult cases (more than 240 million) remain undiagnosed. In 2021 alone, diabetes caused more than 6.7 million deaths and accounted for at least $966 billion in health care spending, or 9% of total spending on adults worldwide.

 

Market Segmentation:

By type: peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy.

By drug type: antidepressants, anticonvulsants, opioids, NSAIDs, others.

By distribution channel: Hospital and clinic pharmacies, retail pharmacies and stores, online pharmacies.

Key Players:

Depomed Pharmaceutical Companies, Eli Lilly, Daiichi Sankyo, Teva Pharmaceutical Industries Ltd., Xenoport, Grünenthal, Johnson and Johnson, Pfizer, GlaxoSmithKline and Boehringer Ingelheim.

Key Developments:

In July 2022, Teva Pharmaceutical Industries Ltd. and NeuroFront Therapeutics (Hong Kong) Limited entered into an exclusive partnership and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, which is being developed to treat diabetes-related neuropathic pain and other neuropathic pain conditions, representing a significant advance in addressing this challenging medical need without relying on opioids.